| Literature DB >> 30374426 |
Eric Fliers1, Barbara Demeneix2, Ashok Bhaseen3, Thomas H Brix4.
Abstract
Several European countries have seen major health issues after a switch from one levothyroxine brand to another, as well as following the introduction of several levothyroxine formulation changes. While the relationship between these health issues and brand or formulation changes merits further investigation, the current position statement on behalf of both health-care providers and patients summarizes recent events in several European countries and provides a number of recommendations to limit the burden for patients, so as to prevent increased health-care consumption and health-care expenses in this context.Entities:
Keywords: European Thyroid Association; Health issues; Levothyroxine products; Thyroid Federation International
Year: 2018 PMID: 30374426 PMCID: PMC6198781 DOI: 10.1159/000493123
Source DB: PubMed Journal: Eur Thyroid J ISSN: 2235-0640